Datopotamab deruxtecan
- Generic Name
- Datopotamab deruxtecan
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2238831-60-0
- Unique Ingredient Identifier
- GD2OWY1DTK
- Background
Datopotamab deruxtecan is under investigation in clinical trial NCT04656652 (Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)).
- Associated Conditions
- -
- Associated Therapies
- -
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
- Conditions
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 740
- Registration Number
- NCT05215340
- Locations
- 🇫🇷
Institut Paoli-Calmettes, Marseille Cedex 9, France
🇺🇸Astera Cancer Care, East Brunswick, New Jersey, United States
🇺🇸Regional Cancer Care Associates LLC, Freehold, New Jersey, United States
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 371
- Registration Number
- NCT04612751
- Locations
- 🇹🇷
Research Site, Malatya, Turkey
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
- Conditions
- Interventions
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 145
- Registration Number
- NCT04526691
- Locations
- 🇯🇵
National Cancer Center Hospital, Tokyo, Japan
🇯🇵Showa Univeristy Hospital, Tokyo, Japan
🇯🇵National Cancer Center Hospital East, Chiba, Japan
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
- Conditions
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 248
- Registration Number
- NCT03944772
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 243
- Registration Number
- NCT03742102
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Conditions
- Interventions
- Drug: Standard TherapyDrug: AMG 386 with or without TrastuzumabDrug: AMG 479 (Ganitumab) plus MetforminDrug: MK-2206 with or without TrastuzumabDrug: T-DM1 and PertuzumabDrug: Pertuzumab and TrastuzumabDrug: GanetespibDrug: ABT-888Drug: NeratinibDrug: PLX3397Drug: Pembrolizumab - 4 cycleDrug: Talazoparib plus IrinotecanDrug: Patritumab and TrastuzumabDrug: Pembrolizumab - 8 cycleDrug: SGN-LIV1ADrug: Durvalumab plus OlaparibDrug: SD-101 + PembrolizumabDrug: Tucatinib plus trastuzumab and pertuzumabDrug: CemiplimabDrug: Cemiplimab plus REGN3767Drug: Trilaciclib with or without trastuzumab + pertuzumabDrug: SYD985 ([vic-]trastuzumab duocarmazine)Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumabDrug: Dan222 + NiraparibDrug: Sarilumab + Cemiplimab + PaclitaxelDrug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumabDrug: AmcenestrantDrug: Amcenestrant + AbemaciclibDrug: Amcenestrant + LetrozoleDrug: ARX788Drug: ARX788 + CemiplimabDrug: VV1 + CemiplimabDrug: Datopotamab deruxtecanDrug: Datopotamab deruxtecan + DurvalumabDrug: ZanidatamabDrug: LasofoxifeneDrug: Z-endoxifenDrug: ARV-471Drug: ARV-471 + LetrozoleDrug: ARV-471 + AbemaciclibDrug: Endoxifen + AbemaciclibDrug: Rilvegostomig + TDXdDrug: AMG 386 and Trastuzumab
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 5000
- Registration Number
- NCT01042379
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Texas, Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Kansas, Westwood, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.